Acorda Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Pharmaceuticals. Acorda is attacking the problem of spinal cord injury from all angles, combining acute treatments with therapies that restore the link between the brain and the damaged spinal cord. The first product to market will likely be 4-aminopyridine (in Phase II), which appears to restore neurological function by improving nerve conduction lost when an injury destroys an axon's myelin sheath.